Harrow (NASDAQ:HROW) Stock Price Expected to Rise, Craig Hallum Analyst Says

Harrow (NASDAQ:HROW) had its price target boosted by research analysts at Craig Hallum from $54.00 to $64.00 in a research note issued on Tuesday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the stock. Craig Hallum’s price target would suggest a potential upside of 33.67% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Cantor Fitzgerald started coverage on Harrow in a report on Friday, July 11th. They set an “overweight” rating and a $76.00 target price for the company. William Blair started coverage on Harrow in a report on Tuesday, June 10th. They set an “outperform” rating for the company. Zacks Research cut Harrow from a “strong-buy” rating to a “hold” rating in a report on Friday, September 12th. BTIG Research raised their target price on Harrow from $62.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, August 14th. Finally, HC Wainwright raised their target price on Harrow from $60.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday, August 13th. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $65.33.

Harrow Stock Down 2.0%

Shares of NASDAQ:HROW opened at $47.88 on Tuesday. The business has a 50-day moving average price of $38.05 and a 200 day moving average price of $31.04. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -191.52 and a beta of 0.33. Harrow has a 12-month low of $20.85 and a 12-month high of $59.23.

Harrow (NASDAQ:HROW) last announced its earnings results on Monday, August 11th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The company had revenue of $63.74 million during the quarter, compared to analysts’ expectations of $64.23 million. Harrow has set its FY 2025 guidance at EPS. Sell-side analysts expect that Harrow will post -0.53 EPS for the current year.

Institutional Investors Weigh In On Harrow

Institutional investors have recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Harrow by 89.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company’s stock worth $2,078,000 after purchasing an additional 29,262 shares during the last quarter. GAMMA Investing LLC lifted its stake in Harrow by 2,401.2% during the first quarter. GAMMA Investing LLC now owns 6,278 shares of the company’s stock worth $1,670,000 after purchasing an additional 6,027 shares during the last quarter. HighTower Advisors LLC lifted its stake in Harrow by 30.5% during the first quarter. HighTower Advisors LLC now owns 13,217 shares of the company’s stock worth $352,000 after purchasing an additional 3,090 shares during the last quarter. Voya Investment Management LLC lifted its stake in Harrow by 4,035.5% during the first quarter. Voya Investment Management LLC now owns 381,461 shares of the company’s stock worth $10,147,000 after purchasing an additional 372,237 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in Harrow by 7.2% during the first quarter. Rhumbline Advisers now owns 42,975 shares of the company’s stock worth $1,143,000 after purchasing an additional 2,879 shares during the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.